Global Erbitux Market Opportunities and Forecast 2023-2030

  •   DLR2890
  •   February, 2022
  •   Pages: 120
  •  Global
Erbitux Market Overview

Colorectal cancer (CRC) is one in all the world's 3 deadliest cancers, with a poor prognosis and a high rate of metastasis. However, the first symptoms of CRC are subtle, and approximately 15–25 p.c of patients with CRC were diagnosed as a complicated stage throughout the initial check-up. As a result, 1/2 all patients with metastatic colorectal cancer (mCRC) ar inoperable, resulting in recurrence and metastasis after treatment.

Additionaly,the fda approved Erbitux in combination with Braftovi (encorafenib) for pre-treated BRAF V600E-mutant metastatic large intestine cancer (CRC). The approval was supported findings from the section three BEACON CRC trial, that revealed that the drug combination resulted in an average overall survival rate of 8.4 months compared to five.4 months within the control cluster of patients who received irinotecan together with Erbitux or FOLFIRI (a chemotherapy combination used to treat metastatic colorectal cancer) in combination with Erbitux. It is a important advancement as a result of this cancer type is very aggressive once it spreads, and all other treatments have failed. Patients whose tumors contain the BRAF V600E mutation have a poor prognosis. once unsuccessful initial therapy, the median survival time is simply four to 6 months, and they frequently have unpleasant symptoms like abdominal swelling or bowel blockage. The trial incontestable that this mixture medical care extends people's lives, delays the onset of those symptoms, and improves their quality of life.

Severe allergic reactions are a serious side impact of Erbitux. allergic reactions are uncommon, however they can be fatal. Low blood pressure, shock, loss of consciousness, and a attack are all possible symptoms. Severe allergic reactions will occur at any point throughout treatment, however they're most typical throughout the primary dose. folks that have a history of tick bites, a meat allergy, or specific antibodies are at a better risk of anaphylactic reactions. Another serious aspect impact of Erbitux may be a attack. Some folks that received Erbitux with radiation therapy or cetuximab with platinum-based chemotherapy and antimetabolite old heart attacks or died unexpectedly. Infusion-related reactions can even end in a attack. once Erbitux was utilized in conjunction with irradiation, the general incidence lately radiation toxicities (of any grade) was over once irradiation was used alone.

Report Metric Details
Market size available for years 2023–2030
Base year considered 2023
Forecast period 2024–2030
Forecast unit Value (USD Million)
Segments covered Type, Application, and Region
Regions covered North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
Companies covered Merck,Bristol-Myers Squibb,Eli Lilly, Manus Aktteva Biopharma LLP,Hubei xinkang pharmaceutical chemical co.,ltd., Array BioPharma Inc.,Wuhan Sunrise Technology Development Company Limited,Chembest Research Laboratories Limited, NKMax ,Pierre Fabre.


The covid-19 Impact on Erbitux Market:

Whereas, the chemicals and accouterments sectors were relatively affected during the pandemic. This is primarily due to uncut demand for chemicals for healthcare, life wisdom, and drawing agents. However, other elements of chemical and material sectors such as types of paints, industrial oil, construction materials are facing reduction in demand. Strict lockdown reflected in a nearly 50-60% reduction in force for raw supply and availability, which directly affected the manufacturing process. Further, halt on numerous end-use diligence directly affected the chemical demand each around the world.
 
Erbitux-market Segment Overview



By Type, Injections are a type of parenteral drug administration because they do not involve absorption within the digestive tract. this allows the medication to be absorbed a lot of quickly and eliminates the first-pass a solution.
 
By Application ,Hospital Pharmacy segment accounted major market share owing to increase hospital infrastructure.
 
Market Analysis, Insights and Forecast – By Type
·       Injection
·       Tablet
·       Other

Market Analysis, Insights and Forecast – By Application
·       Hospital Pharmacy
·       Retail Pharmacies
·       Others

Erbitux Market Regional Overview

Region-wise, in terms of regions north America region accounted for the biggest market share in the global Erbitux market.
The increasing prevalence of colorectal cancer and therefore the presence of key players is predicted to drive the market growth during this region.

According to the American Cancer Society, in each men and women, it's the third leading cause of cancer-related deaths and therefore the second leading cause once men and girls are combined. colorectal of body part cancer cases within the u. s. in 2021 are going to be 104,270 new cases of carcinoma and forty five,230 new cases of body part cancer. it's expected to kill 52,980 people in 2021.

Erbitux Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
 
Erbitux Market Competitor overview

Some key developments and strategies adopted by manufacturers in the Erbituxare highlighted below.

·       In 2020, The National Medical merchandise Administration (NMPA) of China approved Merk’s ERBITUX (cetuximab) for the first-line treatment of patients with perennial and/or pathologic process epithelial cell carcinoma of the top and neck together with platinum-based medical care with fluorouracil.

Erbitux Market, Key Players -

·       Merck,
·       Bristol-Myers Squibb,
·       Eli Lilly,
·       Manus Aktteva Biopharma LLP,
·       Hubei xinkang pharmaceutical chemical co.,ltd.,
·       Array BioPharma Inc.,
·       Wuhan Sunrise Technology Development Company Limited,
·       Chembest Research Laboratories Limited,
·       NKMax
·       Pierre Fabre.

Frequently Asked Questions (FAQ) :

Q1. What is the total CAGR expected to be recorded for the Erbitux market during the forecast period?

Erbitux market is expected to record a CAGR of ~ XX % during the forecast period

Q2. Which segment is projected to hold the largest share in the Erbitux Market?

Injection segment is projected to hold the largest share in the Erbitux Market

Q3. What are the driving factors for the Erbitux market?

The growing demand for the treatment of metastatic colorectal cancer and head and neck cancer , these are main factors driving the growth of automotive lighting market.

Q4. Which Segments are covered in the Erbitux market report?

Type, Application and Region, these segments are covered in the Erbitux market report

Q5. Which are the prominent players offering Erbitux?

Merck,Bristol-Myers Squibb,Eli Lilly, Manus Aktteva Biopharma LLP,Hubei xinkang pharmaceutical chemical co.,ltd., Array BioPharma Inc.,Wuhan Sunrise Technology Development Company Limited,Chembest Research Laboratories Limited, NKMax ,Pierre Fabre
Erbitux Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Erbitux Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Type
        • 5.2.1. Injection
        • 5.2.2. Tablet
        • 5.2.3. Other
      • 5.3. Market Analysis, Insights and Forecast – By Application
        • 5.3.1. Hospital Pharmacy
        • 5.3.2. Retail Pharmacies
        • 5.3.3. Others
      • 5.4. Market Analysis, Insights and Forecast – By Region
        • 5.4.1. North America
        • 5.4.2. Europe
        • 5.4.3. Asia Pacific
        • 5.4.4. Latin America, Middle East, and Africa

      6. North America Erbitux Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Type
        • 6.2.1. Injection
        • 6.2.2. Tablet
        • 6.2.3. Other
      • 6.3. Market Analysis, Insights and Forecast – By Application
        • 6.3.1. Hospital Pharmacy
        • 6.3.2. Retail Pharmacies
        • 6.3.3. Others
      • 6.4. Market Analysis, Insights and Forecast – By Country
        • 6.4.1. UK
        • 6.4.2. Germany
        • 6.4.3. France
        • 6.4.4. Italy
        • 6.4.5. Spain
        • 6.4.6. Russia
        • 6.4.7. Rest of Europe

      7. Asia Pacific Erbitux Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Type
        • 7.2.1. Injection
        • 7.2.2. Tablet
        • 7.2.3. Other
      • 7.3. Market Analysis, Insights and Forecast – By Application
        • 7.3.1. Hospital Pharmacy
        • 7.3.2. Retail Pharmacies
        • 7.3.3. Others
      • 7.4. Market Analysis, Insights and Forecast – By Country
        • 7.4.1. China
        • 7.4.2. India
        • 7.4.3. Japan
        • 7.4.4. Australia
        • 7.4.5. South East Asia
        • 7.4.6. Rest of Asia Pacific

      8. Latin America, Middle East, and Africa Erbitux Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Type
        • 8.2.1. Injection
        • 8.2.2. Tablet
        • 8.2.3. Other
      • 8.3. Market Analysis, Insights and Forecast – By Application
        • 8.3.1. Hospital Pharmacy
        • 8.3.2. Retail Pharmacies
        • 8.3.3. Others
      • 8.4. Market Analysis, Insights and Forecast – By Country
        • 8.4.1. Brazil
        • 8.4.2. Saudi Arabia
        • 8.4.3. UAE
        • 8.4.4. Rest of LAMEA

      9. Competitive Analysis

      • 9.1. Company Market Share Analysis, 2018
      • 9.2. Key Industry Developments
      • 9.3. Company Profile
      • 9.4. Merck
        • 9.4.1. Business Overview
        • 9.4.2. Segment 1 & Service Offering
        • 9.4.3. Overall Revenue
        • 9.4.4. Geographic Presence
        • 9.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 9.5. Bristol-Myers Squibb,
      • 9.6. Eli Lilly,
      • 9.7. Manus Aktteva Biopharma LLP,
      • 9.8. Hubei xinkang pharmaceutical chemical co.,ltd.,
      • 9.9. Array BioPharma Inc.,
      • 9.10. Wuhan Sunrise Technology Development Company Limited,
      • 9.11. Chembest Research Laboratories Limited,
      • 9.12. NKMax ,

      Request for List of Figure


      Research Process

      Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.

      In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization

      FIGURE 1: DLR RESEARH PROCESS

      Primary Research

      Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.

      In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.

      It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.

      Secondary Research

      Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.

      Market Size Estimation

      Both, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.

      Forecast Model